The present invention relates to stable pharmaceutical compositions comprising ivabradine hydrochloride polymorph IV, characterized in that the composition is stabilized by a moisture barrier with a WVTR of less than 0.35 g/m2/day at 38° C./90% RH. The invention further relates to the use of said composition as a medicament, particularly in the treatment of stable angina pectoris and chronic heart failure.
